Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-671 perioperative pembrolizumab plus platinum doublet chemotherapy in resectable NSCLC
2023-504820-24-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Event Free Survival and Overall Survival. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504820-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504820-24-00.